The control of food-related glucose spikes along with a reduction in food intake due to inhibition of gastric emptying led to the approval of GLP-1 RAs for the treatment of diabetes and obesity [2,3]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.